Quick Answer
Phio Pharmaceuticals Corp. reported Research And Development Expense of $4.62 million for the year ending 2025.
- Phio Pharmaceuticals Corp. showed an increase of +26.8% in Research And Development Expense from 2024 to 2025.
- This data is from Phio Pharmaceuticals Corp.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $6.95 million | Q3 2012: $1.21 million | Q1 2013: $13.77 million | Q2 2013: $1.21 million | Q3 2013: $1.23 million | Q1 2014: $1.48 million | Q2 2014: $1.18 million | Q3 2014: $1.46 million | Q1 2015: $2.11 million | Q2 2015: $1.36 million | Q3 2015: $1.73 million | Q1 2016: $1.31 million | Q2 2016: $1.34 million | Q3 2016: $1.46 million | Q1 2017: $1.35 million | Q2 2017: $1.33 million | Q3 2017: $1.49 million | Q1 2018: $1.36 million | Q2 2018: $1.18 million | Q3 2018: $838.0 thousand | Q1 2019: $1.09 million | Q2 2019: $1.15 million | Q3 2019: $1.04 million | Q1 2020: $1.22 million | Q2 2020: $779.0 thousand | Q3 2020: $1.26 million | Q1 2021: $2.43 million | Q2 2021: $1.56 million | Q3 2021: $2.67 million | Q1 2022: $1.59 million | Q2 2022: $1.30 million | Q3 2022: $2.51 million | Q1 2023: $2.13 million | Q2 2023: $1.38 million | Q3 2023: $1.81 million | Q1 2024: $1.15 million | Q2 2024: $866.0 thousand | Q3 2024: $644.0 thousand | Q1 2025: $886.0 thousand | Q2 2025: $1.07 million | Q3 2025: $1.18 million.
- Over the full 15 years of available data (2011 to 2025), Phio Pharmaceuticals Corp.'s Research And Development Expense has declined by 30.3%.
- Historical annual values: Fiscal year 2025: $4.62 million | Fiscal year 2024: $3.64 million | Fiscal year 2023: $6.33 million | Fiscal year 2022: $7.01 million | Fiscal year 2021: $8.89 million | Fiscal year 2020: $3.72 million | Fiscal year 2019: $4.30 million | Fiscal year 2018: $4.33 million | Fiscal year 2017: $5.37 million | Fiscal year 2016: $5.42 million | Fiscal year 2015: $6.93 million | Fiscal year 2014: $5.68 million | Fiscal year 2013: $17.65 million | Fiscal year 2012: $10.45 million | Fiscal year 2011: $6.62 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: